SIGA Technologies - US exercised (stockpile) options are key catalysts
SIGA Technologies announced that the US Department of Health and Human Services has exercised its procurement options for oral and intravenous (IV)...
391 Views
SIGA Technologies - Diamond in the rough amid macro weakness
Ahead of its H123 results and an anticipated period of increased business activity in the second half of the year, we present a preview of SIGA...
406 Views
SIGA Technologies - US stockpiles front and center in Q1 and FY23
SIGA’s Q123 results were largely driven by US TPOXX deliveries under existing contracts. Q123 product revenues of $5.7m ($7.3m in Q122) were...
68 Views
SIGA Technologies - Solid results marked by revenue diversification
SIGA’s FY22 results highlighted underlying revenue diversification and clinical progression during the year. Results were broadly in line with our...
312 Views
SIGA Technologies - Solid Q322, underpinned by international traction
SIGA reported robust Q322 results, with sales momentum driven by international deliveries of oral TPOXX as governments expedited stockpiling to...
338 Views